1 / 21

gnrh agonist in gynaecology gnrha

Physiology

lotus
Download Presentation

gnrh agonist in gynaecology gnrha

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. GnRH agonist In Gynaecology (GnRHa) Dr. Salah Baloul MRCOG Consultant Obstetrician &Gynaecologist Taif Maternity Hospt ,K.S.A

    3. Preparations Different preparations.Nona and Deca peptides Different doses depends on preparation, route of administration(Sub/c injection or implants, I.M and intranasal .. commonest) e.g Nafarelin, Buserlin, Goserelin, Leuprorelin) New preparations works for up to 90 days

    4. Side Effects Breakthrough bleeding (initially) Hypoesterogenic Status : Hot flushes, palpitations, increased sweating, vaginal dryness, change of libido, headache or migraine. Osteoporosis: Duration dependant, 6% possible loss, reversible

    5. Contra-indications Pregnancy Breast feeding Undiagnosed vaginal bleeding

    6. Clinical Application(1) General Gynaecology: Endometriosis Uterine fibroids DUB Central precocious puberty Premenstrual syndrome Hyperandrogenism (PCOS,Hirsutism) Chronic Pelvic pain

    7. Uterine fibroids Before hysterectomy: reduces size by 50%. Correction of anaemia (6.4 to 13.2 gm/dl).vaginal feasibility up to 18l52 size. Before hysteroscopic surgery: 38% size reduction, reduces fluid load risk,HB correction. Possible stromal tumour detection(no or <10% size reduction)

    8. Uterine fibroids cont Before myomectomy: reduces tumour size, intra operative bleeding, and p.operative morbidity. No effect on dissection or enucleation. Duration: 8-12 weeks maximum benefit.delay of surgery for >12 weeks growth to previous size. Subserosal ? Necrosis & acute presentation.

    9. Endometriosis Growth associated with oesrogen & cyclical ovarian steroids . Presentation: Symptoatic: usually pain. Depends on site of implants. Dysmenorrhea. Post coital, pelvic,etc Ovarian cyst Infertility

    10. Endometriosis 2 GnRHa: superior to other medications in symptomatic patients clinically & objectively and in number of patients withdrawal. In ovarian cyst and implants: reduces vasculation , pelvic inflammation and size Infertility: the contribution of the disease itself in infertility depends on its extent. Add back

    11. Dysfunctional uterine bleeding Indications for GnHRa: Failure of conventional treatment Pre operative: *hysterectomy * Endometrial ablation or TCRE ( Render endometrium atrophic and reduces operative time fluid load risk)

    12. Chronic Pelvic Pain Common Gynaecological problem Residual ovary syndrome Pelvic congestion syndrome GnRHa:*reduces vascularity&inflammation *Suppress ovulation, prevents capsular expansion & reduces ovulation pain HRT add back

    13. PMS Aetiology?? Cyclical symptoms: psychological, behavioural, and somatic Conventional treatment:???. Ovariectomy GnRHa: medical ovariectomy Diagnostic. Not with affective disorder Duration:3-6/month,add back HRT May precipitate depression (original symptom!)

    14. Central precocious puberty Idiopathic CPP( GnRH dependant) Peripheral PP ( GnRH independent) Problems: Sexual maturation, Rapid bone growth GnRHa:* Slows sexual development without compromise of sexual potential . *Arrest and normalization of bone growth *Safe , effective and reversible Duration : > 12 months

    15. Hyprandrogenism GnHRa :reduces serum testosterone & andr- osteroidione 50%. No effect on DHES (adrenal).Ovaries has minimal contribution. Has a place in Idiopathic Hirsutism and PCOS ( Not entirely ovarian). Other drugs are more acceptable.

    16. Clinical Application (2) Infertility : Ovulation induction Stimulation for IVF cycles Trigger of ovulation( to prevent OHSS)

    17. infertility In ovulation induction & IVF cycles just prior to HCG use requires luteal phase support Advantage: Avoidance of premature LH surge synchronization of follicular growth. Hence improves quality of ovum collection Organization of cycles and less cancellation

    18. Infertility (cont) Trigger of ovulation: instead of HCG.single or double doses.usually intranasal Longer life results in less luteotrophic effect & development of multiple corpora lutea May reduce the risk of OHSS. Prerequisite: No prior use of GnRHa in the cycle.infertility not related to GnRHa deficiency Pulsatile GnRHa in cycle stimulation

    19. Clinical Application (3) Oncology: Breast malignancy Ovarian malignancy Endometrial malignancy

    20. BREAST: as adjuvant therapy with wide local incision in premenoupasl. Palliative in advance cases( pre & postmenopasusal pts) OVARIAN:Epithelial tumours ,advance cases or refractory after chemotherapy. ENDOMETRIAL: metastaic advance cases. (progesterone & oestrogen receptors +ve)

    21. Conclusion Different preparation with different bioviability and half life. Requires sustained release to result in down regulation effect,and medical ovariectomy. Duration is limited by side effects. Add back therapy may be required. GnRH antagonists may take over its action.

More Related